Match Document Document Title
US20130324587 Factors Controlling Skin and Hair Color  
Use of autophagic activity in regulation of the amount of melanin in a keratinocyte, the control of skin or hair color, or selection of an agent for regulating the amount of melanin in a...
US20120322851 ORAL DELIVERY OF THERAPEUTICALLY EFFECTIVE LNA OLIGONUCLEOTIDES  
The invention provides for LNA oligomers, for the treatment of a metabolic or liver disorder, wherein the LNA oligomer is administered orally in a unit dose of less than 50 mgs/kg, wherein the LNA...
US20150086565 CANCER-RELATED EXTRACELLULAR MATRIX SIGNATURES AND RELATED METHODS AND PRODUCTS  
Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with...
US20140134236 INDIVIDUALIZED CANCER THERAPY  
In certain preferred embodiments, the invention provides methods for treating cancer, which comprise (a) obtaining a specimen of cancer tissue from a patient; (b) obtaining a specimen of normal...
US20150246069 METHOD OF USING SEQUENCE OF ANTAGOMIR FOR DEVELOPING MEDICINE FOR INHIBITING ORAL CANCER CELLS FROM SPREADING  
A method of using sequence of antagomiR for developing medicine for inhibiting oral cancer cells from spreading is provided with the steps of combining a sequence of antagomiR with active...
US20140294929 COMPOSITIONS FOR DELIVERY OF CARGO SUCH AS DRUGS PROTEINS AND/OR GENETIC MATERIALS  
Compositions and methods for delivery of cargo molecules to a patient or subject in need thereof include a proteoliposome carrier vehicle that incorporates an RLIP76 protein and contains the cargo...
US20110020433 COMPOSITIONS FOR DELIVERY OF CARGO SUCH AS DRUGS PROTEINS AND/OR GENETIC MATERIALS  
Compositions and methods for delivery of cargo molecules to a patient or subject in need thereof include a proteoliposome carrier vehicle that incorporates an RLIP76 protein and contains the cargo...
US20120178795 RNAI-MEDIATED INHIBITION OF FRIZZLED RELATED PROTEIN-1 FOR TREATMENT OF GLAUCOMA  
RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.
US20110190381 RNAI-MEDIATED INHIBITION OF FRIZZLED RELATED PROTEIN-1 FOR TREATMENT OF GLAUCOMA  
RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.
US20150141484 Methods, Compositions and Drug Delivery Systems for Intraocular Delivery of siRNA Molecules  
Biocompatible intraocular drug delivery systems in the form of an implant for intraocular administration of siRNA molecules. The drug delivery systems may be placed in an eye to treat or reduce...
US20100311808 METHODS, COMPOSITIONS AND DRUG DELIVERY SYSTEMS FOR INTRAOCULAR DELIVERY OF siRNA MOLECULES  
Biocompatible intraocular drug delivery systems in the form of an implant for intraocular administration of siRNA molecules. The drug delivery systems may be placed in an eye to treat or reduce...
US20120172415 Exon Skipping Therapy for Functional Amelioration of Semifunctional Dystrophin in Becker and Duchenne Muscular Dystrophy  
Methods for stabilizing unstable proteins or for restoring functionality to non-functional or poorly functioning (semi-functional) proteins using exon skipping technology are provided. The methods...
US20120201857 Transdermal delivery system for therapeutics  
The present invention provides a method and product for transdermal delivery of therapeutics, including neurotoxins and methods for use thereof. The method and system comprises pharmaceutical...
US20100316629 Use of gene expression profiling to predict survival in cancer patient  
Gene expression profiling in multiple myeloma patients identifies genes that distinguish between patients with subsequent early death or long survival after treatment. Poor survival is linked to...
US20130289095 SYNTHETIC LETHALITY IN CANCER  
There is described herein compounds, compositions and methods for inducing synthetic lethality in a cancer cell(s).
US20120022140 Method of treating a cancer with a survivin antisense oligonucleotide and paclitaxel  
Provided is a method of treating cancer of the stomach, comprising administering to a patient a therapeutically effective combination of a Survivin antisense oligonucleotide and paclitaxel.
US20140010885 SELF-ASSEMBLING NANOPARTICLE DRUG DELIVERY SYSTEM  
A self-assembling nanoparticle drug delivery system for the delivery of various bioactive agents including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The...
US20120195960 POST-EXPOSURE THERAPY OF INFLUENZA A INFECTIONS  
Poly ICLC or liposome-encapsulated Poly ICLC (LE Poly ICLC) in combination with antisense oligonucleotides (AS) act synergistically in post-exposure prophylaxis or therapy of influenza infections,...
US20110319472 METHODS OF PROGNOSTICATING AND TREATING EWING SARCOMA/PNET AND OTHER NEOPLASMS  
A method of distinguishing between Ewing sarcoma patients having a good prognosis relative to those having a poor prognosis by screening for specific genomic copy number alterations (CNA) isolated...
US20150167002 RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS  
RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela...
US20140364480 RNAi-MEDIATED INHIBITION OF IGF1R FOR TREATMENT OF OCULAR ANGIOGENESIS  
RNA interference is provided for inhibition of IGF1R mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela...
US20130245098 RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS  
RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela...
US20120245217 RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS  
RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela...
US20110257246 RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS  
RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela...
US20120003243 YEAST ECTOPICALLY EXPRESSING ABNORMALLY PROCESSED PROTEINS AND USES THEREFOR  
Disclosed are yeast ectopically expressing abnormally processed proteins and methods of screening to identify compounds that modulate the function of such abnormally processed proteins in yeast....
US20110152352 SMAD PROTEINS CONTROL DROSHA-MEDIATED MIRNA MATURATION  
The invention, in some aspects, relates to compositions and methods useful for modulating expression of miRNAs that are regulated by the TGF-β/BMP signaling pathway. In some aspects, the invention...
US20150080452 Compositions and Methods Related to Protein Displacement Therapy for Myotonic Distrophy  
Disclosed are compositions and methods related to the interaction of polyCUG and polyCCUG repeat RNA and proteins that bind to these repetitive RNA sequences. Also disclosed are methods of...
US20140323545 NITRATED SPHINGOSINE 1-PHOSPHATE 3 RECEPTOR AS A PREDICTOR OF ACUTE LUNG INJURY-ASSOCIATED MORTALITY  
The disclosure relates to a method of determining risk of mortality from Acute Lung Injury (ALI), sepsis, or a combination thereof in a patient, as well as a method of diagnosing ALI in a patient...
US20120231015 FRAGILE X MENTAL RETARDATION PROTEIN (FMRP), COMPOSITIONS, AND METHODS RELATED THERETO  
The invention relates to fragile X mental retardation protein (FMKP), compositions, and methods related thereto. In certain embodiments, the invention relates to treating a neurological disorder...
US20110313233 DOWN-REGULATION OF COLD SHOCK PROTEINS FOR CANCER TREATMENT  
The present invention is in the field of treatment of diseased tissues, including cancerous tissues. In one embodiment, the present invention provides methods of identifying tissues that...
US20130216560 Lipidomic Biomarkers for Identification of High-Risk Coronary Artery Disease Patients  
The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a...
US20110033547 DEHYDRATED CHITOSAN NANOPARTICLES  
The present invention relates to dehydrated nanoparticles comprising chitosan and a nucleic acid. Preferably, the nucleic acid is a siRNA. Dehydrated nanoparticles of the invention have improved...
US20150098926 Methods of Treating Hepatitis C Virus Infection  
The present invention provides methods of treating hepatitis C virus (HCV) infection; methods of reducing the incidence of complications associated with HCV and cirrhosis of the liver; and methods...
US20110243894 METHODS OF TREATING HEPATITIS C VIRUS INFECTION  
The present invention provides methods of treating hepatitis C virus (HCV) infection; methods of reducing the incidence of complications associated with HCV and cirrhosis of the liver; and methods...
US20150050328 METHODS FOR TREATING EYE DISORDERS  
The present invention relates to compositions and methods for inhibiting loss of a retinal ganglion cell in a subject, comprising non-invasively applying to the surface of the eye of the subject...
US20110039789 Use of Huntingtin Protein for the Diagnosis and the Treatment of Cancer  
The present invention relates to new methods of treatment of cancer, in particular of breast cancer, and methods of screening of compounds useful in the treatment of cancer. The present invention...
US20110177096 USE OF GPR151 MODULATORS FOR THE TREATMENT OF PAIN  
The present invention relates to nucleic acid arrays used to detect genes which are up or down regulated following a pain stimulus in a mammal. It further relates to the use of GPR151 in methods...
US20140314787 Treatment for neurodegenerative diseases  
The present application provides a method for treating a neurodegenerative disease in a subject characterised in that the endoplasmic reticulum protein retrotranslocation machinery and/or VCP is...
US20120172409 METHODS AND KITS FOR LINKING POLYMORPHIC SEQUENCES TO EXPANDED REPEAT MUTATIONS  
Methods and kits are provided for determining which single nucleotide polymorphism (“SNP”) variant of an allele of a heterozygous patient is on the same allele as a disease-causing mutation. Also,...
US20150086619 INDIVIDUALIZED CANCER THERAPY  
In certain embodiments, the invention provides methods for treating cancer, comprising: obtaining a specimen of cancer tissue and normal tissue from a patient; extracting total protein; obtaining...
US20100297014 METHOD OF DETECTING THE RISK OF CANCER USING GENETIC MARKERS  
An ex vivo method for the detection of the risk of cancer in a patient, comprising the step of: detecting the expression level of one or more gene sequences identified herein in Table 1, or the...
US20150079105 TREATMENT OF ACUTE INFLAMMATION IN THE RESPIRATORY TRACT  
This invention relates to the field of molecular physiology. Specifically, this invention relates to the prevention and/or treatment of acute inflammation of the respiratory tract, especially...
US20150065559 METHODS FOR DELIVERY OF siRNA TO THE SPINAL CORD AND THERAPIES ARISING THEREFROM  
The present application relates at least in part to methods for the administration of small interfering RNAs (siRNAs) to the spinal cord of a human or animal patient and also to a method of...
US20120252874 METHODS FOR DELIVERY OF SIRNA TO THE SPINAL CORD AND THERAPIES ARISING THEREFROM  
The present application relates at least in part to methods for the administration of small interfering RNAs (siRNAs) to the spinal cord of a human or animal patient and also to a method of...
US20150037251 MAMMALIAN HOMOLOGUES OF FLOWER, THEIR USE IN CANCER DIAGNOSTICS, PREVENTION AND TREATMENT  
The invention relates inhibiting nucleic acids directed at mammalian homologues of the Drosophila fwe gene (Flower) and to antibodies against the respective proteins, and their use in diagnosing,...
US20120244222 OSMOTIC MEDIATED RELEASE SYNTHETIC NANOCARRIERS  
This invention relates, at least in part, to osmotic mediated release barrier-free synthetic nanocarriers and methods of production and use.
US20110293730 Polylactide nanoparticles  
A drug targeting system for administering a pharmacologically active substance to the central nervous system of a mammal across the animal's blood brain barrier. The drug targeting system...
US20110236314 METHOD OF DETECTION AND DIAGNOSIS OF ORAL AND NASOPHARYNGEAL CANCERS  
The present invention relates to cancer and in particular to oral and nasopharyngeal cancers. In particular, the present invention relates to a method of detection and diagnosis of oral squamous...
US20150202222 TREATMENT OF SPINAL CORD INJURY OR TRAUMATIC BRAIN INJURY BY INHIBITION OF AMYLOIDOGENIC PROTEINS AND SYNUCLEIN PROTEIN ACCUMULATION OR AGGREGATION  
Methods for the treatment of spinal cord injury or traumatic brain injury are provided. In certain embodiments, the methods include the use of a molecular tweezers and/or nucleobase oligomer...
US20150125517 miR-200 Family Induces Mesenchymal-to-Epithelial Transition (MET) in Ovarian Cancer Cells  
The present invention provides a method of treating an ovarian cancer, the method comprising delivering one or more miR-200 family members to a mammalian subject in need thereof in an amount...